Plasma-derived versus recombinant Factor VIII concentrates for the treatment of haemophilia A: recombinant is better

被引：0
|
作者：
Franchini, Massimo [1 ]
机构：
[1] Azienda Osped Univ Parma, Serv Immunoematol & Trasfus, Parma, Italy
来源：
BLOOD TRANSFUSION | 2010年 / 8卷 / 04期
关键词：
PREVIOUSLY UNTREATED PATIENTS; IMMUNE TOLERANCE INDUCTION; INHIBITOR DEVELOPMENT; CHILDREN; PURITY; EPIDEMIOLOGY; PRODUCTS; EFFICACY; COMPLEX; RISK;
D O I：
10.2450/2010.0067.10
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：292 / 296
页数：5
相关论文
共 50 条
  • [41] Assessment of inhibitor risk after switching from plasma-derived factor VIII concentrate to recombinant factor VIII (Brasil-RFVIII: brazilian study of inhibitor linked to recombinant factor VIII)
    Prezotti, A.
    Montalvao, S.
    Marques, A.
    Ferreira, C.
    Oliveira, L.
    Villaca, P.
    Ferreira Filho, L.
    Lorenzato, C.
    Medina, S.
    Araujo, F.
    Ozelo, M.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2015, 13 : 366 - 366
  • [42] Comparative stability of plasma derived and recombinant factor VIII
    Mankarious, S
    Parti, R
    THROMBOSIS AND HAEMOSTASIS, 1997, : P2077 - P2077
  • [43] Safety of recombinant and plasma-derived medicinals for the treatment of coagulopathies
    Radosevich, M
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2000, 14 (02) : 459 - +
  • [44] Effect of recombinant and plasma-derived von Willebrand Factor on the procoagulant activity of factor VIII in thrombin generation assays
    Knappe, Sabine
    Till, Susanne
    Scheiflinger, Friedrich
    Dockal, Michael
    HAEMOPHILIA, 2014, 20 : 28 - 28
  • [45] Potency measurement of factor VIII in recombinant concentrates
    Farrugia, A
    Rochfort, P
    Fry, KJ
    Tran, E
    Poulis, M
    HAEMOPHILIA, 1996, 2 (03) : 153 - 159
  • [46] Pharmacokinetics of plasma-derived vs. recombinant FVIII concentrates: a comparative study
    Morfini, M.
    Marchesini, E.
    Paladino, E.
    Santoro, C.
    Zanon, E.
    Iorio, A.
    HAEMOPHILIA, 2015, 21 (02) : 204 - 209
  • [47] PLASMA-DERIVED VERSUS RECOMBINANT HEPATITIS-B VACCINES
    KURTZ, JB
    ALDER, MJ
    MAYONWHITE, RT
    JUELJENSEN, BE
    RODGERS, TM
    BABIC, GM
    LANCET, 1989, 1 (8635): : 451 - 451
  • [48] Immune Responses to Plasma-Derived Versus Recombinant FVIII Products
    Peyvandi, Flora
    Miri, Syna
    Garagiola, Isabella
    FRONTIERS IN IMMUNOLOGY, 2021, 11
  • [49] High-purity, plasma-derived, pasteurized Factor VIII concentrates in the treatment of patients with haemophilia A: update of a long-term pharmacovigilance study
    Klamroth, Robert
    Holzhauer, Susanne
    Heller, Christine
    Sommerer, Patrick
    Kurnik, Karin
    HAEMOPHILIA, 2014, 20 : 24 - 24
  • [50] Pharmacokinetics (PK) of recombinant and plasma-derived factor VIII (FVIII) products in pediatric patients with severe hemophilia A
    Steele, M.
    Chan, A.
    Nagel, K.
    HAEMOPHILIA, 2012, 18 : 35 - 35
12345